Rational Design of a Trimeric April-Based CAR-Binding Domain Enables Efficient Targeting of Multiple Myeloma

Back to Webinars

Featured Speakers: Andrea Schmidts, Post Doctoral Research Fellow, MD Cellular Immunotherapy Program, MGH Cancer Center and Harvard Medical School

What's Inside

In this Webinar we discuss:

Discover how a trimeric extracellular moiety of APRIL has enhanced binding to BCMA and TACI compared with monomeric APRIL when incorporated into a CAR

Explore why trimeric APRIL-based CAR are efficient against BCMA-negative multiple myeloma

Learn why T cells transduced with a trimeric APRIL-based CAR are a promising approach for the treatment of multiple myeloma

Watch the Webinar

Back to the Top